Biologics in the prevention and treatment of graft rejection

Original Article


Biologics are used in solid organ allografting and hematopoietic stem cell transplantation (HSCT) for the induction and maintenance of immunosuppression. In solid organ transplantation, antibodies targeting T cells are part of induction protocols administered for initiation of immunosuppression during organ transfer and during sustained post transplant periods for prevention of graft rejection. Several clinical trials in renal allografting provide data for the efficacy and safety of biologics in this clinical setting. Application of biologics also allows the reduction of calcineurin inhibitors, thereby reducing toxicity and improving long-term graft function. In acute rejection periods, anti T cell antibodies are established in steroid-resistant cases. Strategies interfering with the activity of soluble cytokines are less frequently applied for solid organ transplantation. In HSCT, T cell directed antibodies as part of conditioning protocols improve engraftment and reduce the incidence of detrimental graft vs host disease (GvHD). In acute GvHD, both antibodies targeting T cells and cytokines like TNF-α are established therapeutics for remission induction.


  1. 1.
    Cardella CJ, Cattran D, Fenton SA, Albert S, Robinette M, Cole E (1997) Induction therapy with rabbit antithymocyte sera reduces rejection episodes in immunologically low-risk living donor renal transplant recipients. Transplant Proc 29:29SPubMedCrossRefGoogle Scholar
  2. 2.
    Opelz G (1995) Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative transplant study. Transplantation 60:1220PubMedGoogle Scholar
  3. 3.
    Szczech LA, Berlin JA, Feldman HI (1998) The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-lymphocyte antibody induction therapy study group. Ann Intern Med 128:817PubMedGoogle Scholar
  4. 4.
    Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351:2715PubMedCrossRefGoogle Scholar
  5. 5.
    Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, Dolan S, Kano JM, Mahon M, Schnitzler MA, Woodward R, Irish W, Singer GG (1999) A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 67:1011PubMedCrossRefGoogle Scholar
  6. 6.
    Hardinger KL, Schnitzler MA, Miller B, Lowell JA, Shenoy S, Koch MJ, Enkvetchakul D, Ceriotti C, Brennan DC (2004) Five-year follow up of Thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 78:136PubMedCrossRefGoogle Scholar
  7. 7.
    Goggins WC, Pascual MA, Powelson JA, Magee C, Tolkoff-Rubin N, Farrell ML, Ko DS, Williams WW, Chandraker A, Delmonico FL, Auchincloss H, Cosimi AB (2003) A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 76:798PubMedCrossRefGoogle Scholar
  8. 8.
    Shapiro R, Jordan ML, Basu A, Scantlebury V, Potdar S, Tan HP, Gray EA, Randhawa PS, Murase N, Zeevi A, Demetris AJ, Woodward J, Marcos A, Fung JJ, Starzl TE (2003) Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg 238:520PubMedGoogle Scholar
  9. 9.
    Schroeder TJ, First MR, Mansour ME, Alexander JW, Penn I (1989) Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. Am J Kidney Dis 14:14PubMedGoogle Scholar
  10. 10.
    Norman DJ, Kahana L, Stuart FP Jr, Thistlethwaite JR Jr, Shield CF III, Monaco A, Dehlinger J, Wu SC, Van Horn A, Haverty TP (1993) A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 55:44PubMedCrossRefGoogle Scholar
  11. 11.
    Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, Cendales LK, Tadaki DK, Harlan DM, Swanson SJ (2003) Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76:120PubMedCrossRefGoogle Scholar
  12. 12.
    Knechtle SJ, Fernandez LA, Pirsch JD, Becker BN, Chin LT, Becker YT, Odorico JS, D’Alessandro AM, Sollinger HW (2004) Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery 136:754PubMedCrossRefGoogle Scholar
  13. 13.
    Kirkman RL, Shapiro ME, Carpenter CB, McKay DB, Milford EL, Ramos EL, Tilney NL, Waldmann TA, Zimmerman CE, Strom TB (1991) A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 51:107PubMedCrossRefGoogle Scholar
  14. 14.
    Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP (1997) Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 international study group. Lancet 350:1193PubMedCrossRefGoogle Scholar
  15. 15.
    Sollinger H, Kaplan B, Pescovitz MD, Philosophe B, Roza A, Brayman K, Somberg K (2001) Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 72:1915PubMedCrossRefGoogle Scholar
  16. 16.
    Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D (2004) Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78:584PubMedCrossRefGoogle Scholar
  17. 17.
    Knight RJ, Kerman RH, Schoenberg L, Podder H, Van Buren CT, Katz S, Kahan BD (2004) The selective use of basiliximab versus Thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 78:904PubMedCrossRefGoogle Scholar
  18. 18.
    Nashan B, Light S, Hardie IR, Lin A, Johnson JR (1999) Reduction of acute renal allograft rejection by daclizumab. Daclizumab double therapy study group. Transplantation 67:110PubMedCrossRefGoogle Scholar
  19. 19.
    Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F (2001) Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 72:839PubMedCrossRefGoogle Scholar
  20. 20.
    Dantal J, Ninin E, Hourmant M, Boeffard F, Cantarovich D, Giral M, Wijdenes J, Soulillou JP, Le Mauff B (1996) Anti-CD4 MoAb therapy in kidney transplantation—a pilot study in early prophylaxis of rejection. Transplantation 62:1502PubMedCrossRefGoogle Scholar
  21. 21.
    Haug CE, Colvin RB, Delmonico FL, Auchincloss H Jr, Tolkoff-Rubin N, Preffer FI, Rothlein R, Norris S, Scharschmidt L, Cosimi AB (1993) A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 55:766PubMedCrossRefGoogle Scholar
  22. 22.
    Salmela K, Wramner L, Ekberg H, Hauser I, Bentdal O, Lins LE, Isoniemi H, Backman L, Persson N, Neumayer HH, Jorgensen PF, Spieker C, Hendry B, Nicholls A, Kirste G, Hasche G (1999) A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European anti-ICAM-1 renal transplant study group. Transplantation 67:729PubMedCrossRefGoogle Scholar
  23. 23.
    Hourmant M, Bedrossian J, Durand D, Lebranchu Y, Renoult E, Caudrelier P, Buffet R, Soulillou JP (1996) A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation 62:1565PubMedCrossRefGoogle Scholar
  24. 24.
    Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B (2005) Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353:770PubMedCrossRefGoogle Scholar
  25. 25.
    Port FK, Dykstra DM, Merion RM, Wolfe RA (2005) Trends and results for organ donation and transplantation in the United States, 2004. Am J Transplant 5:843PubMedCrossRefGoogle Scholar
  26. 26.
    Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K (2003) Antibody-mediated rejection criteria—an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 3:708PubMedCrossRefGoogle Scholar
  27. 27.
    Shinn C, Malhotra D, Chan L, Cosby RL, Shapiro JI (1999) Time course of response to pulse methylprednisolone therapy in renal transplant recipients with acute allograft rejection. Am J Kidney Dis 34:304PubMedCrossRefGoogle Scholar
  28. 28.
    Briggs D, Dudley C, Pattison J, Pfeffer P, Salmela K, Rowe P, Tyden G (2003) Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients. Transplantation 75:2058PubMedCrossRefGoogle Scholar
  29. 29.
    Gaber AO, First MR, Tesi RJ, Gaston RS, Mendez R, Mulloy LL, Light JA, Gaber LW, Squiers E, Taylor RJ, Neylan JF, Steiner RW, Knechtle S, Norman DJ, Shihab F, Basadonna G, Brennan DC, Hodge EE, Kahan BD, Kahan L, Steinberg S, Woodle ES, Chan L, Ham JM, Schroeder TJ et al (1998) Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 66:29PubMedCrossRefGoogle Scholar
  30. 30.
    (1985) A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho multicenter transplant study group. N Engl J Med 313:337Google Scholar
  31. 31.
    Norman DJ, Shield CF III, Henell KR, Kimball J, Barry JM, Bennett WM, Leone M (1988) Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection. Transplantation 46:523PubMedCrossRefGoogle Scholar
  32. 32.
    Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O’Laughlin R, Peace D, Jollife LK, Haverty T, Bluestone JA, Thistlethwaite JR Jr (1999) Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1 (Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68:608PubMedCrossRefGoogle Scholar
  33. 33.
    Waid TH, Lucas BA, Thompson JS, McKeown JW, Brown S, Kryscio R, Skeeters LJ (1997) Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial. Transplantation 64:274PubMedCrossRefGoogle Scholar
  34. 34.
    Watschinger B, Pascual M (2002) Capillary C4d deposition as a marker of humoral immunity in renal allograft rejection. J Am Soc Nephrol 13:2420PubMedCrossRefGoogle Scholar
  35. 35.
    Pascual M, Saidman S, Tolkoff-Rubin N, Williams WW, Mauiyyedi S, Duan JM, Farrell ML, Colvin RB, Cosimi AB, Delmonico FL (1998) Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 66:1460PubMedCrossRefGoogle Scholar
  36. 36.
    Rocha PN, Butterly DW, Greenberg A, Reddan DN, Tuttle-Newhall J, Collins BH, Kuo PC, Reinsmoen N, Fields T, Howell DN, Smith SR (2003) Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 75:1490PubMedCrossRefGoogle Scholar
  37. 37.
    Becker YT, Becker BN, Pirsch JD, Sollinger HW (2004) Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 4:996PubMedCrossRefGoogle Scholar
  38. 38.
    Tyden G, Kumlien G, Fehrman I (2003) Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 76:730PubMedCrossRefGoogle Scholar
  39. 39.
    Knoop C, Haverich A, Fischer S (2004) Immunosuppressive therapy after human lung transplantation. Eur Respir J 23:159PubMedCrossRefGoogle Scholar
  40. 40.
    Mueller AR, Pascher A, Platz KP, Braun F, Fandrich F, Rayes N, Seehofer D, Radtke C, Neuhaus P, Kremer B (2004) Immunosuppression following intestinal transplantation. Transplant Proc 36:325PubMedCrossRefGoogle Scholar
  41. 41.
    Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, T Bustami R, Dyke DB (2004) Immunosuppression: practice and trends. Am J Transplant 4(Suppl 9):38PubMedCrossRefGoogle Scholar
  42. 42.
    Hershberger RE, Starling RC, Eisen HJ, Bergh CH, Kormos RL, Love RB, Van Bakel A, Gordon RD, Popat R, Cockey L, Mamelok RD (2005) Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 352:2705PubMedCrossRefGoogle Scholar
  43. 43.
    Pascher A, Klupp J, Langrehr JM, Neuhaus P (2005) Anti-TNF-alpha therapy for acute rejection in intestinal transplantation. Transplant Proc 37:1635PubMedCrossRefGoogle Scholar
  44. 44.
    Goker H, Haznedaroglu IC, Chao NJ (2001) Acute graft-vs-host disease: pathobiology and management. Exp Hematol 29:259PubMedCrossRefGoogle Scholar
  45. 45.
    Ferrara JL, Levy R, Chao NJ (1999) Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 5:347PubMedCrossRefGoogle Scholar
  46. 46.
    Filipovich AH, McGlave PB, Ramsay NK, Goldstein G, Warkentin PI, Kesey JH (1982) Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Lancet 1:1266PubMedCrossRefGoogle Scholar
  47. 47.
    Mitsuyasu RT, Champlin RE, Gale RP, Ho WG, Lenarsky C, Winston D, Selch M, Elashoff R, Giorgi JV, Wells J et al (1986) Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med 105:20PubMedGoogle Scholar
  48. 48.
    Antin JH, Bierer BE, Smith BR, Ferrara J, Guinan EC, Sieff C, Golan DE, Macklis RM, Tarbell NJ, Lynch E et al (1991) Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 78:2139PubMedGoogle Scholar
  49. 49.
    Prentice HG, Blacklock HA, Janossy G, Gilmore MJ, Price-Jones L, Tidman N, Trejdosiewicz LK, Skeggs DB, Panjwani D, Ball S et al (1984) Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 1:472PubMedCrossRefGoogle Scholar
  50. 50.
    Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, Oneto R, Bruno B, Barbanti M, Sacchi N, Van Lint MT, Bosi A (2001) Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98:2942PubMedCrossRefGoogle Scholar
  51. 51.
    Zander AR, Kroger N, Schleuning M, Finke J, Zabelina T, Beelen D, Schwerdtfeger R, Baurmann H, Bornhauser M, Ehninger G, Fauser AA, Kiehl M, Trenschel R, Ottinger HD, Bertz H, Berger J, Kolb HJ, Schaefer UW (2003) ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant 32:355PubMedCrossRefGoogle Scholar
  52. 52.
    Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, Fishlock K, Pagliuca A, Devereux S (2002) Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 100:1715PubMedGoogle Scholar
  53. 53.
    Hale G, Zhang MJ, Bunjes D, Prentice HG, Spence D, Horowitz MM, Barrett AJ, Waldmann H (1998) Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 92:4581PubMedGoogle Scholar
  54. 54.
    Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S (2000) In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96:2419PubMedGoogle Scholar
  55. 55.
    Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, Garcia-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, Parker A, Leon A, Yong K, Sureda A, Hunter A, J Sierra, Goldstone AH, Linch DC, San Miguel JF, Mackinnon S (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100:3121PubMedCrossRefGoogle Scholar
  56. 56.
    D’Sa S, Peggs K, Pizzey A, Verfuerth S, Thuraisundaram D, Watts M, White H, Hale G, Waldmann H, Goldstone A, Mackinnon S, Yong K (2003) T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. Br J Haematol 123:309PubMedCrossRefGoogle Scholar
  57. 57.
    Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, Beatty PG, Doney K, McDonald GB, Sanders JE et al (1990) A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76:1464PubMedGoogle Scholar
  58. 58.
    Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, Sullivan KM, Anasetti C (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962PubMedCrossRefGoogle Scholar
  59. 59.
    Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N, Kersey J, Filipovich A (1990) Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 75:1024PubMedGoogle Scholar
  60. 60.
    Cragg L, Blazar BR, Defor T, Kolatker N, Miller W, Kersey J, Ramsay M, McGlave P, Filipovich A, Weisdorf D (2000) A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 6:441PubMedCrossRefGoogle Scholar
  61. 61.
    Cahn JY, Bordigoni P, Tiberghien P, Milpied N, Brion A, Widjenes J, Lioure B, Michel G, Burdach S, Kolb HJ et al (1995) Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 60:939PubMedCrossRefGoogle Scholar
  62. 62.
    Martin PJ, Nelson BJ, Appelbaum FR, Anasetti C, Deeg HJ, Hansen JA, McDonald GB, Nash RA, Sullivan KM, Witherspoon RP, Scannon PJ, Friedmann N, Storb R (1996) Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 88:824PubMedGoogle Scholar
  63. 63.
    Roy J, McGlave PB, Filipovich AH, Miller WJ, Blazar BR, Ramsay NK, Kersey JH, Weisdorf DJ (1992) Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant 10:77PubMedGoogle Scholar
  64. 64.
    MacMillan ML, Weisdorf DJ, Davies SM, DeFor TE, Burns LJ, Ramsay NK, Wagner JE, Blazar BR (2002) Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 8:40PubMedCrossRefGoogle Scholar
  65. 65.
    Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB (2002) Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 8:155PubMedCrossRefGoogle Scholar
  66. 66.
    Gratama JW, Jansen J, Lipovich RA, Tanke HJ, Goldstein G, Zwaan FE (1984) Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. Clinical results and effect on circulating T lymphocytes. Transplantation 38:469PubMedCrossRefGoogle Scholar
  67. 67.
    Gleixner B, Kolb HJ, Holler E, Liesenfeld S, Riedner C, Hiller E, Seeber C, Kempeni J, Moller A, Knabe H et al (1991) Treatment of aGVHD with OKT3: clinical outcome and side-effects associated with release of TNF alpha. Bone Marrow Transplant 8:93PubMedGoogle Scholar
  68. 68.
    Cole MS, Stellrecht KE, Shi JD, Homola M, Hsu DH, Anasetti C, Vasquez M, Tso JY (1999) HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation 68:563PubMedCrossRefGoogle Scholar
  69. 69.
    Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gooley T, Krueger J, Martin P, Pavlovic S, Sanders J, Slattery J, Levitt D, Storb R, Woolfrey A, Anasetti C (2002) A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99:2712PubMedCrossRefGoogle Scholar
  70. 70.
    Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P, Jerome KR, McCune JS, Storer B, Martin P, Appelbaum F, Abonour R, Westervelt P, Anasetti C (2005) A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 11:465PubMedCrossRefGoogle Scholar
  71. 71.
    Anasetti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis J, Deeg HJ, Doney K, Martin PJ, Nash R, Storb R et al (1994) Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 84:1320PubMedGoogle Scholar
  72. 72.
    Chen HR, Ji SQ, Wang HX, Yan HM, Zhu L, Liu J, Xue M, Xun CQ (2003) Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion. Exp Hematol 31:1019PubMedCrossRefGoogle Scholar
  73. 73.
    Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R (2002) Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 30:899PubMedCrossRefGoogle Scholar
  74. 74.
    Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, Lu JG, Gajewski J, Durett A, Cleary K, Champlin R, Andersson BS, Light S (2000) Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 95:83PubMedGoogle Scholar
  75. 75.
    Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y, Kleiner D, Donohue T, Shalabi R, Carvallo C, Barrett AJ, Geller N, Childs R (2004) Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 124:777PubMedCrossRefGoogle Scholar
  76. 76.
    Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL Jr, Ho VT, Cutler C, Alyea EP, Antin JH, Soiffer RJ (2004) Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 104:1559PubMedCrossRefGoogle Scholar
  77. 77.
    Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C, Steckel S, Cutler C, Fisher DC, Lee SJ, Alyea EP, Ritz J, Soiffer RJ, Antin JH (2004) Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 104:1224PubMedCrossRefGoogle Scholar
  78. 78.
    Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, Parsons SK, Ballen KK, Rimm IJ, Falzarano G et al (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 84:1342PubMedGoogle Scholar
  79. 79.
    Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, Alyea E, McGarigle C, Blazar BR, Sonis S, Soiffer RJ, Ferrara JL (2002) Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100:3479PubMedCrossRefGoogle Scholar
  80. 80.
    Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C et al (1990) Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75:1011PubMedGoogle Scholar
  81. 81.
    Piguet PF, Grau GE, Allet B, Vassalli P (1987) Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 166:1280PubMedCrossRefGoogle Scholar
  82. 82.
    Holler E, Kolb HJ, Mittermuller J, Kaul M, Ledderose G, Duell T, Seeber B, Schleuning M, Hintermeier-Knabe R, Ertl B et al (1995) Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 86:890PubMedGoogle Scholar
  83. 83.
    Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R (2004) Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 104:649PubMedCrossRefGoogle Scholar
  84. 84.
    Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, Baden LR (2003) Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 102:2768PubMedCrossRefGoogle Scholar
  85. 85.
    Andolina M, Rabusin M, Maximova N, Di Leo G (2000) Etanercept in graft-versus-host disease. Bone Marrow Transplant 26:929PubMedCrossRefGoogle Scholar
  86. 86.
    Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP (2002) Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 73:665PubMedCrossRefGoogle Scholar
  87. 87.
    Uberti JP, Ayash L, Ratanatharathorn V, Silver S, Reynolds C, Becker M, Reddy P, Cooke KR, Yanik G, Whitfield J, Jones D, Hutchinson R, Braun T, Ferrara JL, Levine JE (2005) Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant 11:680PubMedCrossRefGoogle Scholar
  88. 88.
    Yanik G, Hellerstedt B, Custer J, Hutchinson R, Kwon D, Ferrara JL, Uberti J, Cooke KR (2002) Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 8:395PubMedCrossRefGoogle Scholar
  89. 89.
    Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J, Leithaeuser M, Hofmeister N, Junghanss C, Casper J, Hartung G, Holler E, Freund M (2005) Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 35:1003PubMedCrossRefGoogle Scholar
  90. 90.
    Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J, Rifkin RM, Abhyankar S, Briggs AD, Burt R, Lipani J, Roskos LK, White JM, Havrilla N, Schwab G, Heslop HE (2001) Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 98:2052PubMedCrossRefGoogle Scholar
  91. 91.
    Jacobsohn DA (2002) Novel therapeutics for the treatment of graft-versus-host disease. Expert Opin Investig Drugs 11:1271PubMedCrossRefGoogle Scholar
  92. 92.
    Stoppa AM, Maraninchi D, Blaise D, Viens P, Hirn M, Olive D, Reiffers J, Milpied N, Gaspard MH, Mawas C (1991) Anti-LFA1 monoclonal antibody (25.3) for treatment of steroid-resistant grade III-IV acute graft-versus-host disease. Transpl Int 4:3PubMedGoogle Scholar
  93. 93.
    van Oosterhout YV, van Emst L, Schattenberg AV, Tax WJ, Ruiter DJ, Spits H, Nagengast FM, Masereeuw R, Evers S, de Witte T, Preijers FW (2000) A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease. Blood 95:3693PubMedGoogle Scholar
  94. 94.
    Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG (1999) Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 340:1704PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Department of Hematology/OncologyUniversity Hospital FreiburgFreiburgGermany

Personalised recommendations